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Summary
Paget’s disease of bone (PDB) is a common metabolic bone
disease characterised by focal areas of increased bone
turnover affecting one or more bones throughout the skeleton,
accompanied by bone pain, bone deformity and an increased
susceptibility to fracture.The cause of PDB is unclear but there
is considerable evidence for a genetic etiology, including famil-
ial clustering and ethnic differences in frequency.A number of
other skeletal disorders have also been described which are
clinically quite similar to PDB, though they are usually charac-
terized by a more severe bone phenotype.The genetic causes
of several of these PDB-like disorders have been elucidated and
have provided clues to the causes of PDB and prompted new
avenues of investigation.In some cases, the genes that cause
these PDB-like disorders have been found to have no effect on
PDB risk, and in others they have been found to confer mildly
increased risk.With the emergence of the SQSTM1 gene as a
common cause of PDB, common molecular pathways involved
i n PDB and PDB-like disorders are emerging, and these are pro-
viding intrigueing new possibilities for investigating the under-
lying molecular defect that leads toP D B .
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Introduction
Paget’s disease of bone (PDB) is a common condition, char-
acterised by focal areas of increased bone turnover affecting
one or more bones throughout the skeleton (1). Clinical fea-
tures include bone pain, deformity, an increased susceptibility
to fracture, and an increased incidence of osteosarcoma. The
lesions of PDB tend to affect the axial skeleton, skull, femora
and tibiae, whereas the bones of the extremities are less fre-
quently involved. Ultrastructural studies of osteoclasts from
pagetic lesions have revealed the presence of ‘virus-like’ nu-
clear inclusion bodies (reviewed in ref. 2) but no intact virus
has been recovered from pagetic bone, and the role of virus-
es in the pathogenesis of PDB remains controversial. There
is accumulating evidence to suggest that genetic factors play
a key role in the pathogenesis of PDB. There are marked eth-
nic differences in susceptibility to PDB (3), which persist after
migration to other countries (4). Familial clustering of Paget’s
disease has also been documented and first degree relatives
of PDB patients run a 7-fold increased risk of developing the
disease compared to controls (5-7).
Recently there has been significant progress in elucidating the
molecular-genetic basis of PDB. Genome-wide scans in multi-
plex families with autosomal dominant PDB have identified
several chromosomal regions with a high probability of linkage
to the disease (8-12). In one of these regions (5q35), mutations
of the SQSTM1 gene have been identified that segregate with
the disease in families (13-20). Important clues to the patho-
genesis of PDB have also come from the study of other bone
diseases that are clinically similar to PDB. This paper will re-
view the clinical presentation of these PDB-like bone diseases
and describe progress to date in understanding their causes.
Particular emphasis will be placed on the how these studies
have provided insights into the cause of PDB.
Familial Expansile Osteolysis (FEO)
In 1988, Osterberg and colleagues (21) described a bone dys-
plasia with many clinical features similar to PDB affecting 40 of
90 members across five generations of a large family from
Northern Ireland, which they named Familial Expansile Osteol-
ysis (FEO; MIM 174810). A clear pattern of autosomal domi-
nant inheritance was evident and radiographs showed both
generalised and focal skeletal changes associated with elevat-
ed serum alkaline phosphatase and urinary hydroxyproline val-
ues, bone pain at radiologically affected sites, tooth loss and
progressive loss of hearing. Virus like inclusion bodies identical
to those in PDB were also identified in the nuclei of osteoclasts
from affected bone.
Many aspects of the disease in this family were dissimilar to
PDB, however. The first presentation of the disease in most
patients was with hearing loss, sometimes from early as four
years of age. Bone pain was also apparent from a much earlier
age of onset than in PDB, beginning in the 2n d decade, and
was so severe in some cases as to be resistant to opiates and
require limb amputation. Focal lesions developed at previously
unaffected sites and progressed along the shafts of long bones
at almost twice the rate of lesions in PDB patients. Lesions
were frequently observed in the forearm, hand and foot bones
but rarely in the axial skeleton. The most noteworthy difference
between FEO and PDB is the apparent uncoupling of the rates
of osteoblast and osteoclast activity in the late stages of FEO,
leading to gross expansion of the medullary cavity and thinning
of the cortex, with almost complete replacement of the bone
with vascularised fatty tissue.
Expansile Skeletal Hyperphosphatasia (ESH)
Whyte and colleagues (22) described a familial metabolic bone
disease in a mother and daughter from Australia, which they
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called Expansile Skeletal Hyperphosphatasia (ESH). Inherited
as a highly penetrant autosomal dominant trait, ESH is charac-
terised by early onset deafness, premature tooth loss and pro-
gressive hyperostotic expansion of the long bones that particu-
larly affects the fingers. Serum alkaline phosphatase and other
markers of bone turnover were considerably elevated in affect-
ed patients. However, ESH was not considered by Whyte to be
a variant of either PDB or FEO because of the episodic hyper-
calcaemia and widespread diffuse bone involvement without the
presence of focal osteolytic lesions. 
Although excessive numbers of osteoblasts and osteoclasts
were seen on bone biopsy, they were not enlarged to the same
extent as seen in PDB. Unfortunately, no osteoclasts were ob-
served in the specimens which were subject to electron mi-
croscopy so the Authors were unable to determine whether they
contained nuclear inclusions. However, the paramyxovirus gene
transcripts reported in blood cells from PDB patients by some
authors (23) were not detected in circulating mononuclear cells
from the ESH patients. 
Early onset PDB
Nakatsuka and colleagues (24) reviewed the clinical presenta-
tion of affected individuals from a Japanese family with a se-
vere form of PDB, whose symptoms emerged in the 2nd or 3rd
decade. The affected individuals had serum alkaline phos-
phatase levels between 2 and 17 times elevated above the
normal range, and affected patients had involvement of the
skull, axial skeleton, small bones of the hands, early onset
deafness and premature tooth loss. In one patient, hypercal-
caemia occurred in association with an episode of immobilisa-
tion. This syndrome had some features in common with PDB,
including axial involvement, skull involvement, and osteoscle-
rotic lesions, but differed from PDB in terms of the young age
of onset, and premature deafness and tooth loss. Other fea-
tures reminiscent of ESH were found including involvement of
the fingers and hypercalcaemia. Linkage analysis in this family
showed allele sharing of markers on chromosome 18q21 in af-
fected individuals, and a positive LOD score, but the family was
to small to confirm or refute the presence of linkage at this lo-
cus. It was concluded that the PDB-like phenotype in this
Japanese family was distinct from classical PDB, but over-
lapped with FEO and ESH.
RANK mutations cause FEO, ESH and early onset PDB
To search for the gene responsible for FEO, Hughes et al.
(25) performed a genome wide screen in 61 members of the
FEO family described by Osterberg et al. (21) using 200 re-
striction fragment length polymorphisms (RFLPs) and 100
highly informative microsatellite polymorphisms. They found
highly significant evidence of linkage on chromosome
18q21.1-q22 (<5cM; maximum LOD score of 11.53 at
D18S64). This region contains the gene encoding the Recep-
tor Activator of NF-kB (RANK), T N F R S F 1 1 A, which is known
to be expressed on osteoclast precursor cells (26, 27). RANK
is the sole receptor for RANK-ligand (RANKL), which is ex-
pressed on the surface of osteoblasts and is essential and
sufficient (in the presence of small amounts of Macrophage
Colony Stimulating Factor, MCSF) for the differentiation of
osteoclast precursors into mature, bone-resorbing osteoclasts
(reviewed in 28). The interaction between these two mem-
brane-bound factors is central to the regulation of bone re-
s o r p t i o n .
Considering the importance of the RANKL-RANK interaction
as a regulator of osteoclast activity, Hughes et al. (29)
screened the coding regions, proximal promoter and intron-ex-
on boundaries of TN F R S F 1 1 A in all members of a Northern
Irish (21) and two other FEO families and identified an 18-bp
duplication (84dup18) affecting the RANK signal peptide that
segregated with the disease in all affected members of these
families. They did not find the mutation in 158 healthy con-
trols. Palenzuela et al. (30) and Johnson-Pais et al. (15) sub-
sequently confirmed that the 84dup18 mutation is a cause of
FEO in families from Spain and the US respectively. Following
this discovery, Whyte and Hughes (31) performed mutation
screening of the RANK gene in two ESH patients (22). In both
cases, they found a 15-bp duplication that was allelic to the
FEO mutation (84dup15), and which was not present in 70 un-
affected controls. The 84dup18 FEO and 84dup15 ESH muta-
tions are predicted to elongate the RANK signal peptide by six
and five amino-acids respectively, and expression of the re-
combinant form of the 84dup18 mutant in a mammalian cell
system showed increased constitutive activation of RANK,
possibly resulting from lack of normal cleavage of the signal
peptide (29). A different duplication mutation also affecting the
RANK signal peptide (75dup27) was found in the Japanese
family previously described with the phenotype of early onset
PDB (24), which again segregated with the disease in affected
individuals. In common with the mutations that cause FEO and
ESH mutations, this duplication elongated the signal peptide,
preventing cleavage and was shown to activate NFkB signal-
ing. 
These observations naturally led other groups to search for
RANK mutations in individuals with classical PDB. Whyte et al.
(22) failed to find any RANK mutations in 70 sporadic PDB cas-
s and Hughes et al. (29) reported the same result in 90 spo-
radic PDB cases. Confirming these observations, Kormas et al.
(32) performed mutation screening of the RANK gene in 82
sporadic and 23 familial cases of PDB from Australia but did
not find any mutations. Marco-Mingot et al. (33) also failed to
find disease-causing mutations in 18 PDB patients from Spain.
Sparks et al. (34) found no RANK mutations in sporadic or fa-
milial PDB cases, or in osteosarcomas, a well known complica-
t on of PDB. This work and other reports of non-linkage of PDB
to chromosome 18q21 (9, 35) have led to the general conclu-
sion that mutations in the RANK gene are not a common cause
of PDB.
Juvenile Paget’s Disease (JPD)
JPD [MIM 239000; also known as Idiopathic Hyperphosphata-
sia, or Familial Hyperphosphatasemia] is a rare autosomal re-
cessive condition with a severe phenotype, of which about 50
cases have been reported worldwide. The disease is charac-
terised by elevated rates of bone turnover, skeletal deformity,
bone pain, and an increased risk of pathological fracture.
Symptoms are evident from early infancy, when the disease
presents with skeletal deformity and failure to thrive. This is fol-
lowed by the development of skull enlargement, walking diffi-
culty, progressive sensorineural deafness, kyphosis and ac-
etabular protrusion. Disease severity generally increases dur-
ing adolescence, but a mild form been described in some pa-
tients (36).
Levels of serum alkaline phosphatase and other bone turnover
markers are greatly elevated in JPD, reflecting the generalized
increase in bone turnover. The bones are enlarged and the
normal trabecular architecture of healthy bone is replaced with
an unusual, but characteristic pattern of abnormal parallel tra-
b cular plates that are contribute to the reduced bone strength
(37, 38). Whilst JPD has certain similarities to classical PDB, it
is clearly a more severe condition as attested by the early age
at onset and marked bone deformity developing during child-
hood. 














OPG mutations cause JPD
Recent studies have clarified the molecular basis of JPD.
Whyte and colleagues described two apparrently unrelated
Navajo patients with JPD in whom they postulated that the
disease might be due to a defect in osteoprotegerin (OPG)
function (39). OPG is a member of the TNF-receptor super-
family, which acts as a soluble decoy receptor for RANK-lig-
and, blocking osteoclast activation and bone resorption (28).
Mice lacking OPG develop severe osteoporosis due to exces-
sive osteoclast activity (40, 41), and overexpression of OPG
leads to osteopetrosis due to inhibition of osteoclast forma-
tion (42). Whyte and colleagues first excluded mutations in
the RANK gene as a cause of the JPD and then attempted to
perform mutation analysis of the OPG gene, T N F R S F 1 1 B, in
these patients. In so doing, they discovered that the entire
OPG gene, along with a 100 kb stretch of flanking chromo-
some 8q24, had been homozygously deleted (39). In another
study, Cundy et al. (43) described a family of Iraqi origin, in
which three of nine siblings had JPD. They performed a
genome-wide scan and found evidence of suggestive linkage
on chromosome 8q24 (LOD score 2.21). Sequencing T N -
F R S F 1 1 B in this family revealed a homozygous 3bp deletion
in all three affected siblings, which was predicted to result in
the loss of an aspartate residue from the OPG protein. This
residue is highly conserved in members of the TNF-receptor
superfamily, suggesting that it is essential for normal function,
and these Authors found that the mutant OPG was unable to
prevent osteoclastic resorption in a bone culture system.
To evaluate the role of OPG in classical PDB, Wuyts et al. (44)
looked for evidence of mutations or polymorphisms in OPG in
24 sporadic and 4 familial PDB cases. They identified several
single nucleotide polymorphisms (SNPs) in the coding regions,
and whilst none of these were found to cause PDB, a common
SNP was found in intron 2 that was overrepresented in PDB
patients compared with controls. In a similar study, Trainor et
al. (45) described an association between PDB and a polymor-
phic marker close to the gene. Recently, Daroszewska et al.
(46) confirmed the link between polymorphic variation in OPG
and PDB by finding a significant association between a mis-
sense polymorphism affecting exon 3 of OPG and PDB. There-
fore, it appears that subtle variation in OPG can also increase
risk of classical PDB, possibly by affecting OPG regulation or
secretion.
Another strong candidate gene for PDB and related syn-
dromes is RANKL since mice deficient in this protein have se-
vere osteopetrosis, with complete lack of osteoclasts (47,48).
Conversely, mice injected subcutaneously with recombinant
RANKL develop severe hypercalcaemia and a reduction in
bone volume due to an increase in osteoclast size and multin-
uclearity (48). Despite the importance of RANKL in osteoclast
biology, mutations and polymorphisms of RANKL have not
yet been identified in association with PDB or related disor-
ders. 
Inclusion body myopathy, Paget’s disease
and frontotemporal dementia
An unusual syndrome of inclusion body myopathy, Paget’s dis-
ease and frontotemporal dementia (IBMPFD) was described by
Kimonis et al. (49) and Kovach et al. (50) in a series of families
from the US where the disease was inherited in an autosomal
dominant fashion [MIM 605382]. Myopathy was the most
prominent symptom, presenting with weakness, muscle atro-
phy and occasionally pain. Affected patients often experienced
difficulty raising the arms and climbing stairs, and in some cas-
es, complete immobility occurred. The mean age at onset of
symptoms was in the fifth decade, similar to that in classical
PDB. Muscle biopsies revealed variation in muscle fibre size,
grouped regions of muscle fibre atrophy, and intracellular blue-
rimmed vacuoles with punctate staining debris and cytoplasmic
protein accumulations (51). Whilst Kimonis and colleagues
were first to described the specific syndrome of IBMPFD, it is
interesting to note that PDB has also been reported to be asso-
ciated with myopathy in the absence of dementia by other au-
thors (52-54).
Like classical PDB, bone lesions in IBMPFD typically affect the
spine, pelvis and skull, and biochemical evaluation shows in-
creased serum levels of alkaline phosphatase and elevated uri-
nary markers of bone resorption. On radiological examination,
there is coarse trabeculation of the affected bone, cortical
thickening and focal lesions consistent with PDB, and individu-
als treated with bisphosphonates or calcitonin show clinical im-
provement. Dementia typically follows the symptoms of myopa-
thy and PDB and is characterised by language difficulties and
changes in personality, including apathy, increased agitation,
nomia (inability to remember names). In many cases, auditory
or visual hallucinations occur. These clinical features are asso-
ciated with atrophy of the frontal cortex. Although detailed brain
histology has not been performed to determine if the dementia
in IBMPFD is also associated with inclusion bodies, protein ag-
gregation in neurons is thought to be a feature of all neurode-
generative disorders (reviewed in 55). 
Mutations in the VCP gene cause IBMPFD
Linkage analysis in IBMPFD families initially excluded loci in-
volved in limb girdle muscular dystrophy, PDB, cardiomyopathy
and amyotrophic lateral sclerosis. A genome-wide screen iden-
tified significant linkage to chromosome 9p13 spanning a re-
gion of 5.5 Mb (maximum LOD score 3.64) (50). Having ex-
cluded several genes in this region that are involved in muscle
function (56), Watts et al. (57) screened 13 IBMPFD families
for mutations in Valosin-Containing Protein (VCP), which is in-
volved in several intracellular signalling pathways, including
ubiquitin (UB)-mediated protein degradation (58) (reviewed in
59). They identified six different disease-segregating mutations
affecting the highly conserved CDC48 domain, which is in-
volved in UB-binding (60, 61). They propose that IBMPFD mu-
tations in VCP are relatively subtle, and their impact only
reaches a critical disease threshold in response to oxidative
stress and old age. This may also apply to the question of why
PDB only emerges in later life.
The discovery of mutations in the UB-binding domain of VCP is
i eresting because of the fact that mutations affecting the
ubiquitin-associated (UBA) domain of SQSTM1 are a common
cause of late onset PDB. In addition to its role as a required
scaffold protein for NFk B-mediated osteoclast activation (62,
63), SQSTM1 is thought to be involved in trafficking UB-tagged
proteins to the proteasome through its UBA domain (64, 65).
Abnormal UB-mediated catabolism is known to cause a num-
ber of diseases in several tissues, particularly the brain (66),
and such disease are frequently characterised by UB-contain-
ing inclusion bodies. These inclusion bodies are thought to be
composed of accumulations of undegraded protein, and Watts
et al. (57) found that VCP localised to protein aggregates in
muscle cells from IBMPFD patients. These findings are rele-
vant to PDB because pagetic osteoclasts have long been
shown to contain unidentified cytoplasmic or nuclear inclusion
bodies, which have to date been interpreted as paramyxovirus
fragments (67-71). Work is ongoing to clarify whether these in-
clusions contain the SQSTM1 protein, p62, but it is interesting
to note that VCP and p62 have individually been found to co-lo-
calise with UB-containing nuclear inclusions in several neu-
r degenerative disorders (72-76). It is currently unclear
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whether VCP mutations or polymorphisms contribute to the
pathogenesis of late onset PDB.
Concluding remarks
Over the last five years, major advances have been made in
understanding the genetic basis of PDB and related disorders.
Analysis of candidate genes that lie in regions with strong link-
age to PDB is ongoing but in SQSTM1 we now have an impor-
tant clue to the underlying defect which may help us select
candidates more purposefully. While the involvement of
SQSTM1 in UB-mediated proteolysis and the possible implica-
tions this may have for the discovery of new PDB genes is a
hot topic at the moment, it is worth noting that SQSTM1’s role
in the RANK-NFk B pathway has still not been fully worked out.
Perhaps it is too much of a coincidence that the only gene
known to cause PDB is also an indispensable member of
bone’s most critical osteoclastogenic signaling cascade.
It has been established for some time that TRAF6, another in-
dispensable member of the RANK-NFk B pathway, has impor-
tant E3 ubiquitin ligase activity and is a substrate of lysine-63-
linked polyubiquitin chains, which are required for signal
transduction through this pathway. The relationship between
TRAF6 and S Q S T M 1 in the RANK pathway is not yet clear,
but they are known to interact in a way that is required for ac-
tivation of the IL-1 pathway, which is capable of supporting
lower levels of osteoclastogenesis in the absence of RANKL-
RANK stimulation. It may turn out that there is a critical inter-
action between TRAF6-polyUB and the UBA domain of
S Q S T M 1, but we must wait for this to be clarified before we
can select new candidates for PDB from this system. We can
conclude that PDB and a number of related disorders are due
to mutations in various parts of the RANKL-RANK-NFk B sys-
tem and it may turn out that other members of this pathway
also cause PDB.
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